BLA vs NDA: The Difference Between the Two FDA Applications
An NDA (New Drug Application) is how a company asks the FDA to approve a chemically made drug, usually a small-molecule pill. A BLA (Biologics License Application) is for biologics: drugs made from living cells, like antibodies, vaccines, and cell and gene therapies. Both run on the same PDUFA review clock. The big difference for investors comes after approval: biologics get 12 years before a copy can be approved, small molecules usually get 5.
The difference between an NDA and a BLA
| NDA vs BLA | |
| Used for | NDA: chemically made drugs, most pills. BLA: biologics such as antibodies, vaccines, gene and cell therapies |
| Law behind it | NDA: the Food, Drug and Cosmetic Act. BLA: the Public Health Service Act |
| Review clock | Same for both: about 10 months standard, 6 months priority, set by the PDUFA date |
| Protection before copies | NDA: usually 5 years for a new chemical. BLA: 12 years |
| Copies | NDA drugs get generics. BLA drugs get biosimilars, which are harder and costlier to make |
Why it matters to investors
The review itself feels the same. A company files, the FDA accepts, a PDUFA date is set, and the answer is an approval or a CRL.
What changes is the long game. A biologic has 12 years before a biosimilar can be approved, and even then biosimilars take years to win share because they are expensive to make. A small-molecule drug can face cheap generics much sooner. That is part of why big drug makers pay so much for antibody and gene therapy companies.
Who at the FDA reviews each one
Most NDAs and therapeutic biologics such as antibodies are reviewed by the Center for Drug Evaluation and Research (CDER). Vaccines, blood products and cell and gene therapies go to the Center for Biologics Evaluation and Research (CBER). It rarely changes the outcome, but you will see both names in company press releases.
A fun edge case: insulin was approved under NDAs for decades, then in March 2020 it was moved over and treated as a biologic.
sNDA and sBLA: new uses for an approved drug
Once a drug is approved, a company files a supplemental application (sNDA or sBLA) to add a new disease or patient group to the label. These are often smaller news than the first approval, but for a company with one product, a new indication can double its market.
See it live: See every upcoming FDA decision and filter the calendar by drug type, biologics included.
Open the PDUFA Calendar →Frequently asked questions
An NDA is the application for chemically made drugs, while a BLA is for biologics made from living cells, such as antibodies, vaccines and gene therapies. Both are reviewed on the same PDUFA timelines, but biologics get 12 years of protection from copies after approval, against about 5 years for a new small-molecule drug.
Not by design. The standard for safety and effectiveness is the same. Biologics do add questions about how the product is made, and manufacturing problems are a common reason for a Complete Response Letter on a BLA.
A biosimilar is a close copy of an approved biologic. It is approved through a shorter pathway, but it can only be approved 12 years after the original biologic, and it costs much more to make than a generic pill.
A supplemental NDA or BLA asks the FDA to add something to an approved drug's label, most often a new disease or patient group.
About 10 months for a standard review and 6 months for a priority review, counted from when the FDA accepts the filing. For most new drugs that means a decision roughly 12 or 8 months after the company submits.
Educational content only. Not financial advice. Past results don't predict future ones.